|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 January 2002, Vol. 99, No. 2, pp. 609-617
NEOPLASIA
HLA-G protein up-regulation in primary cutaneous lymphomas is
associated with interleukin-10 expression in large cell T-cell
lymphomas and indolent B-cell lymphomas
Mirjana Urosevic,
Joerg Willers,
Beatrix Mueller,
Werner Kempf,
Guenter Burg, and
Reinhard Dummer
From the Department of Dermatology, University Hospital
Zurich, Switzerland.
Primary cutaneous lymphomas (CLs) constitute a spectrum of diseases
characterized by a clonal accumulation of lymphocytes in the skin. Most
CLs display a Th2 cytokine profile, including expression of
interleukin-10 (IL-10). Because the up-regulation of HLA-G, a
nonclassical class Ib molecule inducible by IL-10, might account for
the immunescape of the malignant clone, HLA-G and IL-10 expression has
been investigated in 45 cases of primary CL (10 of B-cell and
35 of T-cell origin) with quantitative polymerase chain reaction (PCR)
and immunohistochemistry. HLA-G message was present in all cutaneous
B-cell (CBCL) and T-cell (CTCL) lymphomas evaluated.
Immunohistochemistry revealed HLA-G protein expression in 23 (51%) of
45 cases (7 of 10 CBCL, 16 of 35 CTCL). While in CBCL mostly indolent
types displayed HLA-G positivity, in CTCL HLA-G expression was
associated with high-grade histology and advanced stage of the disease.
Except for neoplastic and infiltrating lymphocytes, other cells such as
macrophages and dendritic cells showed HLA-G immunoreactivity.
Furthermore, IL-10 protein expression was demonstrated in 16 (73%) of 22 HLA-G+ cases, which correlated with HLA-G
protein presence (P < .001). HLA-G up-regulation
together with IL-10 expression in CL might additionally contribute to
the evasion of immunosurveillance and facilitate the transition from
low- to high-grade lymphomas.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M I Torres, M A Lopez-Casado, J Luque, J Pena, and A Rios
New advances in coeliac disease: serum and intestinal expression of HLA-G
Int. Immunol.,
May 1, 2006;
18(5):
713 - 718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Rouas-Freiss, P. Moreau, S. Ferrone, and E. D. Carosella
HLA-G Proteins in Cancer: Do They Provide Tumor Cells with an Escape Mechanism?
Cancer Res.,
November 15, 2005;
65(22):
10139 - 10144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Leleu, G. Le Friec, T. Facon, L. Amiot, R. Fauchet, B. Hennache, V. Coiteux, I. Yakoub-Agha, S. Dubucquoi, H. Avet-Loiseau, et al.
Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
Clin. Cancer Res.,
October 15, 2005;
11(20):
7297 - 7303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Nuckel, V. Rebmann, J. Durig, U. Duhrsen, and H. Grosse-Wilde
HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia
Blood,
February 15, 2005;
105(4):
1694 - 1698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Le Friec, F. Gros, Y. Sebti, V. Guilloux, C. Pangault, R. Fauchet, and L. Amiot
Capacity of myeloid and plasmacytoid dendritic cells especially at mature stage to express and secrete HLA-G molecules
J. Leukoc. Biol.,
December 1, 2004;
76(6):
1125 - 1133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dummer, J. C. Hassel, F. Fellenberg, S. Eichmuller, T. Maier, P. Slos, B. Acres, P. Bleuzen, V. Bataille, P. Squiban, et al.
Adenovirus-mediated intralesional interferon-{gamma} gene transfer induces tumor regressions in cutaneous lymphomas
Blood,
September 15, 2004;
104(6):
1631 - 1638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I.-M. Shih and R. J. Kurman
Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis
Am. J. Pathol.,
May 1, 2004;
164(5):
1511 - 1518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Torres, M. Le Discorde, P. Lorite, A. Rios, M. A. Gassull, A. Gil, J. Maldonado, J. Dausset, and E. D. Carosella
Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease
Int. Immunol.,
April 1, 2004;
16(4):
579 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urosevic, J. Kamarashev, G. Burg, and R. Dummer
Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2
Blood,
March 1, 2004;
103(5):
1796 - 1798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Singer, V. Rebmann, Y.-C. Chen, H.-T. Liu, S. Z. Ali, J. Reinsberg, M. T. McMaster, K. Pfeiffer, D. W. Chan, E. Wardelmann, et al.
HLA-G Is a Potential Tumor Marker in Malignant Ascites
Clin. Cancer Res.,
October 1, 2003;
9(12):
4460 - 4464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moreau, G. Mouillot, P. Rousseau, C. Marcou, J. Dausset, and E. D. Carosella
HLA-G gene repression is reversed by demethylation
PNAS,
February 4, 2003;
100(3):
1191 - 1196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Ibrahim, Y. Allory, F. Commo, B. Gattegno, P. Callard, and P. Paul
Altered Pattern of Major Histocompatibility Complex Expression in Renal Carcinoma: Tumor-Specific Expression of the Nonclassical Human Leukocyte Antigen-G Molecule Is Restricted to Clear Cell Carcinoma While Up-Regulation of Other Major Histocompatibility Complex Antigens Is Primarily Distributed in All Subtypes of Renal Carcinoma
Am. J. Pathol.,
February 1, 2003;
162(2):
501 - 508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
